Group 1 - European stocks gained as investor sentiment improved due to better-than-expected US personal spending data, despite President Trump's plans to impose tariffs on patented drugs [1] - The Stoxx Europe 600 Index rose at the close, with the healthcare sector recovering to gain 0.1% after Trump's announcement of a 100% duty on patented drugs effective Oct. 1, unless producers build manufacturing plants in the US [1] - Novo Nordisk A/S and Zealand Pharma A/S experienced declines following the tariff announcement [1] Group 2 - European equities have been fluctuating within a narrow range as investors assess the outlook for US interest-rate cuts, with resilient consumer behavior noted [2] - The Federal Reserve's preferred inflation gauge showed slower growth in August compared to the previous month [2] Group 3 - Equity strategist Wolf von Rotberg suggested that the lack of detail in the tariff announcement and the potential limited impact on drug prices may not warrant a reduction in pharma exposure [3] - Portfolio manager Sophie Huynh indicated that the situation could present a good entry point for adding to European stocks rather than shorting them, emphasizing the need to consider the broader context despite potential nervousness in the pharma sector [4]

President Donald Trump announced a new set of tariffs targeting patented and branded drugs. https://t.co/vrTviXR29Y ...